Literature DB >> 33107978

Real-world effectiveness and tolerability of dupilumab in adult atopic dermatitis: a single-centre, prospective 1-year observational cohort study of the first 100 patients treated.

A V Sears1, R T Woolf1, E Gribaleva1,2, W Abdelrahman1, S Robbie3, B Menon4, B Kirkham4, C H Smith1,5, A E Pink1.   

Abstract

Entities:  

Year:  2021        PMID： 33107978     DOI： 10.1111/bjd.19631

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN： 0007-0963            Impact factor:   9.302


× No keyword cloud information.
  6 in total

1.  Dupilumab-associated arthralgia in patients with aspirin-exacerbated respiratory disease.

Authors:  Lorena Miss Ozuna; Tessa Ryan; Jillian C Bensko; Tanya M Laidlaw; Kathleen M Buchheit
Journal:  Ann Allergy Asthma Immunol       Date:  2022-02-03       Impact factor: 6.347

2.  Real-World Effectiveness of Dupilumab in Atopic Dermatitis Patients: Analysis of an Electronic Medical Records Dataset.

Authors:  Lawrence F Eichenfield; April Armstrong; Emma Guttman-Yassky; Peter A Lio; Chi-Chang Chen; Dionne M Hines; Catherine B McGuiness; Sohini Ganguli; Dimittri Delevry; Debra Sierka; Usha G Mallya
Journal:  Dermatol Ther (Heidelb)       Date:  2022-05-11

Review 3.  A Literature Review of Real-World Effectiveness and Safety of Dupilumab for Atopic Dermatitis.

Authors:  Masahiro Kamata; Yayoi Tada
Journal:  JID Innov       Date:  2021-07-30

4.  Review of dupilumab-associated inflammatory arthritis: An approach to clinical analysis and management.

Authors:  Ryan Jay; Jaimie Rodger; Matthew Zirwas
Journal:  JAAD Case Rep       Date:  2022-01-06

5.  Dupilumab Treatment of Atopic Dermatitis in Routine Clinical Care: Baseline Characteristics of Patients in the PROLEAD Prospective, Observational Study.

Authors:  Diamant Thaçi; Andrea Bauer; Ralph von Kiedrowski; Florian Schenck; Konstantin Ertner; Sophie Möller; Anja Fait; Mike Bastian; Matthias Augustin
Journal:  Dermatol Ther (Heidelb)       Date:  2022-08-19

6.  A 52 weeks dupilumab treatment for moderate to severe atopic dermatitis in Korea: long-term efficacy and safety in real world.

Authors:  Dong Hyek Jang; Seok Jae Heo; Hyung Don Kook; Dong Heon Lee; Hye Jung Jung; Mi Yeon Park; Jiyoung Ahn
Journal:  Sci Rep       Date:  2021-12-07       Impact factor: 4.379
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.